HCP
DNLI icon

Hexagon Capital Partners’s Denali Therapeutics DNLI Stock Holding History

Hexagon Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$204 – 500
2025
Q1 		$204 Buy
15
+3
+25% +$57 ﹤0.01% 1755
2024
Q4 		$245 Buy
+12
New +$307 ﹤0.01% 1753

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hexagon Capital Partners's DNLI Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 15 shares — an estimated $204 sold.

Hexagon Capital Partners first reported a position in DNLI in Q4 2024 and held it in 2 quarters. The position peaked at $245 in Q4 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 15 Denali Therapeutics shares in Q2 2025, an estimated $204.
  • Hexagon Capital Partners first reported a position in Denali Therapeutics in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Denali Therapeutics position peaked at $245 in Q4 2024.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.